What do we mean when we talk about the long-term outcome of bone marrow transplants for acute myeloid leukemia (AML)? The majority of studies present actuarial survival curves for the first 5 or at best 10 years after BMT. This presentation raises a number of questions: What is the actual longterm disease-related outcome after allogeneic BMT in AML? How does it compare to conservative treatments? Can survival plateaus be achieved? Finally, what is the functional capacity of long-term survival with AML?
To address these questions we initiated an intent-to-treat study of 135 AML patients that were referred to Princess Margaret Hospital between 1979 and 1993 for induction therapy. All age eligible patients were enrolled. During the study period the upper age limit was increased stepwise from 40 to 45, 50 and finally 55 years. Enrollment was completed in 1993 and the study evaluated in 1999, 20 years after treatment of the first patient. Out of the total 135 patients, 10 failed from early death, defined as having succumbed within the first 30 days after initiation of therapy. The remaining 125 patients and their families were tissue typed. Related donors were identified for 51/125 patients, and of these, 46 were transplanted. Twenty-four of 51 patients are alive. In contrast, only 14/74 of the patients without related donors are alive. The 10-year event-free survival (EFS) for patients with donors was 43%, compared to 14% for patients without donors. EFS for patients achieving a complete response (CR) were 52% and 20%, respectively. The EFS for patients transplanted in CR1 amounted to 70% at 10 years. 1 The study demonstrated a significant long-term benefit for patients undergoing allogeneic transplant for their AML. The transplant was particularly beneficial for patients transplanted in CR1. These data raise the question, whether or not patients with related donors differ in their survival expectancy from patients without related donors.
A similar, EORTC-GIMEMA study examined the importance of having an HLA-matched donor available. The 831 patients evaluated were all less than 46 years old and had survived at least 8 weeks from diagnosis. Allogeneic transplants were performed in 181/295 patients with related donors. The EFS evaluated at 6 years was longer for patients with donors (46%) compared to patients without donors (33%), however, the overall survival did not differ significantly (48% vs 40%). 2 The actual level of these survival data may depend on a number The observation of sustained survival plateaus has to be interpreted with caution. Often they are based on a relatively small numbers of patients, precluding the detection of infrequent late events. To examine this question we increased our database to 245 patients by also including patients solely referred for transplantation. The increased number of cases resulted in the detection of late events that reduced the survival for every 5 years by about 10%. 1 Sustained decreases in survival of similar magnitude are reported in other larger studies. The International Bone Marrow Transplant Registry examined the outcome of a total of 6691 patients with various forms of leukemia, as well as aplastic anemia. Every patient that had survived the first 2 years (n = 2058) was considered for the long-term assessment. The relative mortality rate was 19% at 2 years, 10.2% at 5 years, and 4.5% at 9 years. 4 Late events included disease recurrences; transplant-related complications such as chronic graft-versus-host disease, infections, organ failures, and emergence of new problems, such as secondary malignancies. Duell et al 5 used the EBMT data base (European Group for Blood and Marrow Transplantation) to assess morbidity and mortality of 798 transplant patients. For the 55 patients who survived for at least 5 years, mortality was 8% at 10 years and 14% at 15 years. The cumulative mortality rate for the whole cohort of patients continued to rise by about 10% every 5 years, which is very similar to our own data. One very important issue concerns malignancies in long-term survivors. A EBMT study published recently by Kolb et al 6 compared the incidence of new malignancies in the general population to 1036 consecutive patients that were more than 5 years from transplant for various diseases. After a median follow-up of about 11 years, 55/1036 (5%) patients were identified who had developed new neoplasms resulting in an actuarial incidence of 3.5% at 10 years and 12.8% at 15 years. The difference was highly significant.
Are these downward trends in survival rates seen after transplants different from survival rates observed in patients with AML that have achieved a lengthy disease-free interval without a transplant? This question was addressed by De Lima et al, 7 who studied a group of 215 patients with AML that had lived disease-free for at least 3 years in CR1 or CR2. The follow-up ranged from 2 weeks to 14 years. Ten to 15% of patients died within the first 5 years of becoming eligible for study. Similar to transplant data a plateau was not observed and late events included disease recurrence, organ failures and secondary malignancies. These data are consistent with a classic study conducted by Nicholson et al, 8 comparing the survival of pediatric cancer patients who had survived at least 5 years since their diagnosis to that of their siblings. A total of 2319 patients and 3255 siblings serving as control subjects were enrolled between 1945 and 1974. The overall death rate from all causes of cancer survivors was higher than that of sibling controls followed during the same time interval. It is of note that the risk of dying of causes other than the primary disease was increased more than three-fold.
The higher death toll in successfully treated cancer patients appears to be a common phenomenon and is observed after conservative therapy as well as after transplantation. It is now time to ask the questions, what parameters in these heavily treated patients represent risk factors for relapse, treatmentrelated complications, and secondary malignancies, and what surveillance strategies should be developed to recognize patients at risk?
